cnbc.com web signal

SpaceX, OpenAI, Anthropic IPO Rush Risks Market Overload

openai xai anthropic ipo markets bubble valuation

Key insights

  • SpaceX, OpenAI, and Anthropic combined are targeting over $3.75 trillion in valuation across near-simultaneous IPO listings.
  • Michael Burry has actively expanded short positions against AI ahead of these listings, signaling institutional bearish conviction.
  • Neither OpenAI nor Anthropic currently generates profits, making their valuations dependent on forward revenue projections holding.

Why this matters

For AI founders and technical leaders, this IPO cluster sets a public market pricing floor — or ceiling — for the entire sector, and a poor reception for any one of the three would reprice private round expectations industry-wide within weeks. The profitability challenge flagged by de Gale is not abstract: compute costs at OpenAI and Anthropic remain structurally high enough that the path to margin is still unproven at scale, and public market investors demand different evidence than venture capital does. If Burry's short position proves prescient, the downstream effect hits AI infrastructure spending as enterprise customers slow procurement commitments tied to vendor financial stability.

Summary

Three of the most valuable private companies in the world are converging on public markets at roughly the same time, and Wall Street is getting nervous about the math. SpaceX is targeting a $1.75 trillion valuation, OpenAI is eyeing roughly $1 trillion, and Anthropic is also moving toward a listing — together representing a supply of new equity unlike anything markets have absorbed simultaneously in recent memory. Institutional portfolio managers would be forced to rebalance existing holdings to make room, creating selling pressure across an already concentrated U.S. equity market. Essentially: (SpaceX, OpenAI, Anthropic) are competing for the same institutional capital at the same moment. - Jim Cramer invoked dot-com-era excess, pointing to valuations built on projected rather than current profits. - Michael Burry has expanded his AI short position specifically ahead of these listings. - BlueBox portfolio manager William de Gale put it plainly: if OpenAI and Anthropic cannot demonstrate real profitability, the valuation architecture collapses. The stress test for AI's investment thesis isn't a technical benchmark — it's whether three companies can absorb trillions in public capital without triggering the correction skeptics have been modeling for two years.

Potential risks and opportunities

Risks

  • If OpenAI's IPO prices below its last private round valuation of roughly $300 billion, late-stage venture investors face markdown pressure across their entire AI portfolio within the same quarter.
  • A simultaneous multi-trillion listing event could force index funds and passive vehicles into concentrated selling of existing tech holdings to rebalance, amplifying drawdowns in Nvidia, Microsoft, and Alphabet in the near term.
  • Anthropic faces heightened scrutiny as the smallest of the three by valuation, and weak demand for its offering could be read by enterprise customers as a signal of competitive positioning weakness relative to OpenAI.

Opportunities

  • Institutional short-sellers and volatility desks at firms like Citadel and Two Sigma are positioned to profit from the rebalancing turbulence if all three listings cluster within the same 60-day window.
  • Mid-tier AI infrastructure providers with proven unit economics — such as CoreWeave post-IPO or profitable vertical AI SaaS companies — gain relative attractiveness to allocators burned by unprofitable mega-cap listings.
  • Financial advisors and secondary market platforms (Forge Global, Carta) see increased demand from employees and early investors in all three companies looking to derisk before lockup expirations.

What we don't know yet

  • Whether OpenAI or Anthropic have disclosed credible paths to operating profitability in their pre-IPO S-1 filings or roadshow materials.
  • The degree to which sovereign wealth funds and non-U.S. institutional buyers are being targeted to absorb supply that domestic allocators cannot.
  • Whether any coordinating mechanism exists between the three companies to stagger listing timelines and reduce equity supply overlap.